Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI

Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04347135

Enrollment

Registered

2020-04-15

Start date

2022-10-07

Completion date

2024-04-30

Last updated

2024-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

Researchers are trying to improve the detection of endometriosis using F-18 FES PET/MRI imaging.

Interventions

DRUGF-18 FES

F-18 FES PET/MRI for detection of endometriosis.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

\- Premenopausal women (18-50) with endometriosis

Exclusion criteria

* Postmenopausal women * AP diameter when lying supine greater than 32 cm (too large for PET/MRI) * Unable to undergo PET/MRI for any reason (metal implants, severe claustrophobia) * Unable to receive IV Gadolinium contrast for any reason (renal failure eGFR \< 60, contrast allergy) * Pregnant (Urine test will be provided for all patients)

Design outcomes

Primary

Measure	Time frame	Description
Detection of Endometriosis	24 months	Comparisons will be made descriptively between conventional MRI imaging, FES PET/MRI imaging and surgical/pathologic findings. Outcome data include number of detected lesions, differences in the accuracy for detection of active disease versus inactive fibrosis, and confidence score.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026